Kristen G. Valencia Deray

Kristen G. Valencia Deray

Auto-generated profile, based on publicly available information

Kristen G. Valencia Deray

Division of Infectious Diseases Department of Pediatrics Baylor College of Medicine Houston Texas USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2024 in Journal of the Pediatric Infectious Diseases Society
Verified
Journal Article
Open access
PDF file
KDKristen G Valencia Deray
Kristen G Valencia Deray
LDLara A Danziger-Isakov
Lara A Danziger-Isakov
KDKevin J. Downes
Kevin J. Downes
Despite current prophylaxis regimens, cytomegalovirus (CMV) is common in hematopoietic cell transplantation (HCT) and solid organ transplantation (SOT) and remains a significant cause of morbidity and mortality. Newer antiviral medications are reshaping the landscape for prevention and treatment of CMV DNAemia, infection, and disease. Letermovir is approved for CMV prevention in adult HCT patients and is attractive due to the absence of marrow suppression seen with ganciclovir/valganciclovir. Letermovir should not be routinely used for CMV treatment due to its low threshold for resistance. Maribavir is approved for the treatment of refractory or resistant CMV disease in HCT and SOT recipients ≥12 years of age, though it has no current role in CMV prevention. More research is needed to fully elucidate the roles, efficacy, and safety of these newer agents in prevention and treatment of CMV in pediatric transplant recipients.

1 September 2021 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
KDKristen G. Valencia Deray
Kristen G. Valencia Deray
KHKathleen E. Hosek
Kathleen E. Hosek
DCDivya Chilukuri
Divya Chilukuri
JDJordan R. Dunson
Jordan R. Dunson
DSDavid R. Spielberg
David R. Spielberg
CBClaire E. Bocchini
Claire E. Bocchini
Despite prevention strategies, cytomegalovirus (CMV) remains a common infection in pediatric solid organ transplant recipients (SOTR). We sought to determine the frequency, associations with, and long-term outcomes of CMV DNAemia in pediatric SOTR. We performed a single-center retrospective cohort study, including 687 first time SOTR ≤ 21 years receiving universal prophylaxis from 2011-2018. Overall, 159 (23%) developed CMV DNAemia, the majority occurring after completing primary prophylaxis. CMV disease occurred in 33 (5%) SOTR, 25 (4%) with CMV syndrome and 10 (1%) with proven/probable tissue-invasive disease. CMV contributed to the death of 3 (0.4%) patients (all lung). High-risk (OR 6.86 [95%CI, 3.6 – 12.9]) and intermediate-risk (4.36 [2.3 – 8.2]) CMV status and lung transplantation (4.63 [2.33 – 9.2]) were associated with DNAemia on multivariable analysis. DNAemia was associated with rejection in liver transplant recipients (p<0.01). DNAemia was not associated with an increase in graft failure, all-cause mortality, or other organ-specific poor outcomes. We report one of the lowest rates of CMV disease after SOTR, showing that universal prophylaxis is effective and should be continued. However, we observed CMV morbidity and mortality in a subset of patients, highlighting the need for research on optimal prevention strategies. This study was IRB approved.

26 July 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
SDSalih Demirhan
Salih Demirhan
FMFlor M. Munoz
Flor M. Munoz
KDKristen G. Valencia Deray
Kristen G. Valencia Deray
CBClaire E. Bocchini
Claire E. Bocchini
LDLara Danziger-Isakov
Lara Danziger-Isakov
BHBetsy C. Herold
Betsy C. Herold
Optimal dosing of valganciclovir (VGCV) for cytomegalovirus (CMV) prevention in pediatric solid organ transplantation recipients (SOTR) is controversial. Dosing calculated based on body surface area and creatinine clearance (BSA) is recommended but simplified body weight (BW) dosing is often prescribed. We conducted a retrospective six center study to compare safety and efficacy of these strategies in the first-year post-transplantation. There were 100 (24.2%) pediatric SOTR treated with BSA and 312 (75.7%) with BW dosing. CMV DNAemia was documented in 31.0% versus 23.4% (p=0.1) at any time during the first year and breakthrough DNAemia in 16% versus 12.2% (p=0.3) of pediatric SOTR receiving BSA versus BW dosing, respectively. However, neutropenia (50% versus 29.3%, p<0.001), lymphopenia (51% versus 15.0%, p<0.001) and acute kidney injury causing treatment modification (8.0% versus 1.8%, p<0.001) were documented more frequently during prophylaxis in pediatric SOTR receiving BSA versus BW dosing. The adjusted odds ratio of VGCV attributed toxicities comparing BSA and BW dosing was 2.3 [95% CI, 1.4-3.7] for neutropenia, 7.0 [95% CI, 3.9-12.4] for lymphopenia, and 4.6 [95% CI, 2.2-9.3] for premature discontinuation or dose reduction of VGCV, respectively. Results demonstrate that BW dosing is associated with significantly less toxicity without any increase in CMV DNAemia.

28 June 2024 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
MFMarc Foca
Marc Foca
SDSalih Demirhan
Salih Demirhan
FMFlor M Munoz
Flor M Munoz
KDKristen G Valencia Deray
Kristen G Valencia Deray
CBClaire E Bocchini
Claire E Bocchini
BHBetsy C. Herold
Betsy C. Herold
Valganciclovir is the only approved antiviral for cytomegalovirus (CMV) prevention in pediatric solid organ transplantation (SOT). Additional approaches may be needed to improve outcomes. A multicenter retrospective study from 2016 to 2019 was conducted of pediatric SOT recipients in whom at least 3 months of valganciclovir prophylaxis was planned. Episodes of CMV DNA in blood (DNAemia), CMV disease, drug-related toxicities, as well as other infections in the first year posttransplant and demographic and clinical data were collected. CMV DNAemia in the first year after prophylaxis or during prophylaxis (breakthrough) was analyzed by multivariate hazard models. Among the 749 patients enrolled, 131 (17.5%) had CMV DNAemia at any time in the first year; 85 (11.4%) had breakthrough DNAemia, and 46 (6.1%) had DNAemia after prophylaxis. CMV disease occurred in 30 (4%). In a multivariate model, liver transplantation compared to kidney or heart, intermediate or high risk based on donor/recipient serologies, neutropenia, and valganciclovir dose modifications attributed to toxicity were associated with increased risk of total and/or breakthrough DNAemia. Bacteremia was also associated with increased hazard ratio for CMV DNAemia. In a separate multivariate analysis, rejection occurred more often in those with breakthrough CMV DNAemia (P = .002); liver transplants, specifically, had increased rejection if CMV DNAemia occurred in the first year (P = .004). These associations may be bidirectional as rejection may contribute to infection risk. CMV DNAemia in the first year posttransplantation occurs despite valganciclovir prophylaxis and is associated with medication toxicity, bacteremia, and rejection. Pediatric studies of newer antivirals, especially in higher-risk subpopulations, appear to be warranted.

27 March 2022 in Pediatric Transplantation
Verified
Journal Article
Closed access
KDKristen G. Valencia Deray
Kristen G. Valencia Deray
MTMargaret G. Taylor
Margaret G. Taylor
MBMelissa M. Blessing
Melissa M. Blessing
CBClaire E. Bocchini
Claire E. Bocchini
ESErica K. Schallert
Erica K. Schallert
RMRossana Malatesta Muncher
Rossana Malatesta Muncher

1 January 2024 in Sage Open Medical Case Reports
Verified
Journal Article
Open access
KDKristen G Valencia Deray
Kristen G Valencia Deray
RKRichard Kellermayer
Richard Kellermayer
AGAlexis C Gomez
Alexis C Gomez
KPKalyani R Patel
Kalyani R Patel
PIPeace Imani
Peace Imani
AOAlvaro Orjuela
Alvaro Orjuela
Malakoplakia is a rare, chronic granulomatous disease that mainly affects the genitourinary system of immunocompromised adults. It is caused by a bactericidal deficit in macrophages and, therefore, the treatment includes antimicrobials that reach high concentrations in macrophages. To our knowledge, we present the first case of malakoplakia in a pediatric solid organ transplant recipient. Our patient is a 15-year-old male renal transplant recipient who presented with recurrent diarrhea. Blood, urine, and gastrointestinal pathogen panel testing were positive for enteroaggregative Escherichia coli. A colonoscopy revealed diffuse malakoplakia. He had a complete resolution of symptoms with trimethoprim-sulfamethoxazole therapy. Unfortunately, his malakoplakia recurred after 9 months prompting the transition of therapy to oral gentamicin with subsequent remission. Malakoplakia should be considered in the differential of solid organ transplant recipients with recurrent gastrointestinal infections.